News

Insights into Celestica's Options Activity and Market Trends

Insights into Celestica's Options Activity and Market Trends

Understanding Celestica's Market Movements

The financial landscape for Celestica has been capturing the attention of traders and investors alike. Recently, a notable bearish sentiment has emerged among significant investors, commonly referred to as whales, reflecting a cautious approach to Celestica's stock performance.

Recent analysis of the options activity for Celestica (NYSE: CLS) uncovered eight significant trades. A breakdown of these transactions indicates that around 25% of these options trades were initiated with bullish expectations, while a substantial 62% revealed a more bearish outlook among investors.

Analyzing Trade Details

Among the trades observed, four were put options generating a total investment of approximately $682,296, contrasted against four call options that totaled around $242,120. This disparity highlights the prevailing market sentiment, with more traders opting for puts, which signifies a potential decline in stock prices.

Price Target Insights

Analyzing the trading volume and open interest for these contracts offers valuable insights into the market's perspective. It appears that over the past three months, investors have been targeting a price range for Celestica between $100.00 and $110.00, reflecting where they anticipate the stock might stabilize or fluctuate.

Volume and Open Interest Trends

The examination of volume and open interest trends plays a crucial role in understanding liquidity and investor interest. For Celestica's options, significant trades have highlighted activity within the strike price range of $100.00 to $110.00, revealing where market players see value or risk.

Recent Options Activity

Reviewing Celestica's call and put volume over the last 30 days illustrates the evolving sentiment around this stock. Investors are actively participating, with recent trades providing insights into the potential direction for Celestica's prices.

Observing the Largest Options Trades

Symbol PUT/CALL Trade Type Sentiment Expiration Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
CLS PUT SWEEP BEARISH 03/21/25 $7.00 $6.90 $7.00 $100.00 $310.80K 5.00K 703
CLS PUT SWEEP BULLISH 03/21/25 $7.40 $7.00 $7.00 $100.00 $176.00K 5.00K 262
CLS PUT SWEEP BEARISH 03/21/25 $7.00 $6.90 $7.00 $100.00 $151.30K 5.00K 919
CLS CALL TRADE BEARISH 03/07/25 $7.20 $6.10 $6.10 $105.00 $122.00K 49 200
CLS CALL SWEEP NEUTRAL 03/21/25 $5.80 $5.40 $5.80 $105.00 $57.40K 288 5

Overview of Celestica

Celestica Inc specializes in providing comprehensive supply chain solutions. The company operates through two key segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). Within ATS, major areas of focus include Aerospace and Defense, Industrial, Health Tech, and Capital Equipment businesses, recently noted for its semiconductor and robotics solutions. The Connectivity & Cloud segment covers a broad range of communication and enterprise markets, generating the bulk of Celestica's revenue.

Current Position of Celestica

  • At present, the stock is trading at $100.27, reflecting a downward movement of -6.34% with a trading volume of 1,183,699 shares.
  • Technical indicators suggest that the stock may be in an oversold position.
  • Anticipation builds as the next earnings report is expected to be released soon.

Market Experts Weigh In

Insights from three market analysts reveal a consensus target price for Celestica of approximately $155.67. This analysis indicates a generally positive outlook despite current market fluctuations.

Smart money flows are essential in options trading, where strategic moves can signal potential market movements. Analysts have issued insightful ratings for Celestica, with one maintaining an Overweight rating at a target of $157, while another sets their Outperform rating with a target of $160. Additionally, a Buy rating has been sustained with a target price of $150.

Options trading entails a certain level of risk compared to traditional stock trading, but it also opens doors for higher return potentials. Proficient traders can reduce risk by staying informed, adjusting positions, and tracking multiple indicators closely. For those interested in following the latest movements in Celestica's options, tools offering real-time alerts can prove invaluable.

Frequently Asked Questions

What is Celestica's stock ticker symbol?

Celestica's stock is listed under the ticker symbol CLS on the New York Stock Exchange.

What do the recent options trades for Celestica indicate?

Recent options trades show a predominantly bearish sentiment among investors, with more puts being bought compared to calls.

What price range have investors targeted for Celestica?

Investors have recently targeted a price range between $100.00 and $110.00 for Celestica based on options activity.

How is Celestica performing in the current market?

Currently, Celestica's stock price is down by -6.34% to $100.27, showing signs of being oversold.

What are the analysts' views on Celestica stock?

Analysts generally maintain positive outlooks for Celestica, with target prices nearing $155.67 based on recent evaluations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 89

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 27

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 63

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 85

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 98

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 66

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 46

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
John Wong's Decade as Estate Planning Specialist

Updated Category News Views 68

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 146

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Medical Diagnostics with Advanced AI Defense

Updated Category News Views 163

Innovative Defense System for Medical Digital Twins This method enables medical digital twins to achieve 98% accuracy in breast cancer prediction, even under adversarial attacks. Medical digital twins are sophisticated virtual models that mirror real biological systems, offering healthcare professionals a powerful tool for predicting and diagnosing diseases. However,...

Continue Reading
Honeywell's Big Play: Amended Deal to Acquire Catalyst Tech

Updated Category News Views 186

What's the Deal with Honeywell? Honeywell (NASDAQ: HON) just mixed things up a bit—like, they changed the game plan on their agreement to acquire Johnson Matthey's Catalyst Technologies. The original asking price took a haircut, getting whittled down from £1.8 billion to £1.325 billion. I mean, who wouldn't appreciate a discount nowadays? Right? The long stop date is...

Continue Reading
Transformation of Senior Living Market Driven by AI Trends

Updated Category News Views 404

Transforming the Senior Living Market: The Role of AI The senior living sector is poised for substantial evolution, with market expansion projected at USD 130.9 billion between 2025 and 2029. The driving force behind this growth is the aging baby boomer population that is reshaping the landscape of senior living options. The market is growing at a compound annual growth...

Continue Reading
Saudi Arabia Eyes the Future with AAM Feasibility Study

Updated Category News Views 11

Bracing for Saudi Arabia's Air Mobility Leap Here's something you don't see every day: Boeing Saudi Arabia and the Kingdom's top aviation folks are calling in the big guns—partnering with SkyGrid and KAUST—for a serious dive into the how-tos of Advanced Air Mobility (AAM) across Saudi airspace. This isn't just about slapping some high-tech drone stickers on existing...

Continue Reading
Investment Boost: Live Oak Ventures Supports AI Innovations

Updated Category News Views 263

Live Oak Ventures Announces a Strategic Investment Recently, Live Oak Ventures, the investment arm of Live Oak Bancshares, Inc., made headlines by investing in Cascading AI, Inc. (Casca), a leading platform that revolutionizes loan applications and originations through responsible artificial intelligence. Collaboration Aimed at Streamlining Loan Processes Live Oak Bank is...

Continue Reading